PAI-2 as a Prognostic Marker in Lung Cancer
Author Information
Author(s): H Yoshino, Y Endo, Y Watanabe, T Sasaki
Primary Institution: Kanazawa University, Kanazawa, Japan
Hypothesis
Is decreased expression of plasminogen activator inhibitor 2 (PAI-2) associated with lymph node metastasis in primary lung cancer?
Conclusion
Decreased expression of PAI-2 is significantly correlated with lymph node metastasis and poor prognosis in lung cancer patients.
Supporting Evidence
- PAI-2 expression was detected in only half of the lung cancer cases studied.
- Lower PAI-2 levels were significantly associated with lymph node metastasis.
- Patients with low PAI-2 expression had a worse prognosis compared to those with higher levels.
Takeaway
This study found that lower levels of a protein called PAI-2 in lung cancer tissues can mean the cancer is more likely to spread and that patients may not do as well.
Methodology
The study examined PAI-2 expression in lung cancer tissues using immunohistochemical staining and RT-PCR techniques.
Participant Demographics
{"mean_age":63.8,"sex_distribution":{"male":76,"female":29},"histology":{"squamous_cell_carcinoma":40,"adenocarcinoma":53,"large_cell_carcinoma":6,"small_cell_carcinoma":6}}
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website